Utilization of copper complexes involving 2-phenyl-3-hydroxy-4(1H)-quinolinone and 1,10-phenanthroline derivatives for the preparation of drugs for the treatment of tumour diseases

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F17%3A73584104" target="_blank" >RIV/61989592:15310/17:73584104 - isvavai.cz</a>

Výsledek na webu

<a href="https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20131016&DB=EPODOC&locale=en_EP&CC=EP&NR=2650000A1&KC=A1&ND=5" target="_blank" >https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20131016&DB=EPODOC&locale=en_EP&CC=EP&NR=2650000A1&KC=A1&ND=5</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Utilization of copper complexes involving 2-phenyl-3-hydroxy-4(1H)-quinolinone and 1,10-phenanthroline derivatives for the preparation of drugs for the treatment of tumour diseases

Popis výsledku v původním jazyce

The utilization of the copper complexes in the oxidation state +II and their crystal-solvates having the general formula [Cu(qui)(R n phen)]X, and expressed by the structural formula (I), where the symbol qui stands for the 2-phenyl-3-hydroxy-4(1H)-quinolinonate anion(1-), symbol R n , where n = 1-4, stands for a substituent or substituents on 1,10-phenathroline (phen), where R1 is a substituent independently chosen from the group of: hydrogen, 4-methyl, 5-methyl, 5-nitro, 5-chloro, if R1 is 5-methyl, then R2 is 6-methyl, if R1 is 4-phenyl, then R2 is 7-phenyl, if R1 is 3-methyl, then R2 is 4-methyl, R3 is 7-methyl and R4 is 8-methyl, expressed by the specific formulas as [Cu(qui)(4-methylphen)]X, [Cu(qui)(5-methylphen)]X, [Cu(qui)(5-nitrophen)]X, [Cu(qui)(5-chlorophen)]X, [Cu(qui)(5,6-dimethylphen)]X, [Cu(qui)(4,7-diphenylphen)]X, [Cu(qui)(3,4,7,8-tetramethylphen)]X, and the symbol X stands for a monoanion independently chosen from the group of: F - , Cl - , Br - , I - , NO 3 - , BF 4 - , BPh 4 - , HCOO - , CH 3 COO - , ClO 4 - , HSO 4 - ; for the preparation of drugs for the treatment of human lung carcinoma and/or human cervix epitheloid carcinoma and/or human malignant melanoma and/or human ovarian carcinoma and/or human cisplatin- resistant ovarian carcinoma and/or human prostate carcinoma.

Název v anglickém jazyce

Utilization of copper complexes involving 2-phenyl-3-hydroxy-4(1H)-quinolinone and 1,10-phenanthroline derivatives for the preparation of drugs for the treatment of tumour diseases

Popis výsledku anglicky

The utilization of the copper complexes in the oxidation state +II and their crystal-solvates having the general formula [Cu(qui)(R n phen)]X, and expressed by the structural formula (I), where the symbol qui stands for the 2-phenyl-3-hydroxy-4(1H)-quinolinonate anion(1-), symbol R n , where n = 1-4, stands for a substituent or substituents on 1,10-phenathroline (phen), where R1 is a substituent independently chosen from the group of: hydrogen, 4-methyl, 5-methyl, 5-nitro, 5-chloro, if R1 is 5-methyl, then R2 is 6-methyl, if R1 is 4-phenyl, then R2 is 7-phenyl, if R1 is 3-methyl, then R2 is 4-methyl, R3 is 7-methyl and R4 is 8-methyl, expressed by the specific formulas as [Cu(qui)(4-methylphen)]X, [Cu(qui)(5-methylphen)]X, [Cu(qui)(5-nitrophen)]X, [Cu(qui)(5-chlorophen)]X, [Cu(qui)(5,6-dimethylphen)]X, [Cu(qui)(4,7-diphenylphen)]X, [Cu(qui)(3,4,7,8-tetramethylphen)]X, and the symbol X stands for a monoanion independently chosen from the group of: F - , Cl - , Br - , I - , NO 3 - , BF 4 - , BPh 4 - , HCOO - , CH 3 COO - , ClO 4 - , HSO 4 - ; for the preparation of drugs for the treatment of human lung carcinoma and/or human cervix epitheloid carcinoma and/or human malignant melanoma and/or human ovarian carcinoma and/or human cisplatin- resistant ovarian carcinoma and/or human prostate carcinoma.

Druh

P - Patent

CEP obor

—

OECD FORD obor

10402 - Inorganic and nuclear chemistry

Projekt

<a href="/cs/project/LO1305" target="_blank" >LO1305: Rozvoj centra pokročilých technologií a materiálů</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Číslo patentu nebo vzoru

EP2650000 B1

Vydavatel

EPO_1 -

Název vydavatele

European Patent Office

Místo vydání

Munich, The Hague, Berlin, Vienna, Brussels

Stát vydání

—

Datum přijetí

15. 3. 2017

Název vlastníka

Univerzita Palackého

Způsob využití

B - Výsledek je využíván orgány státní nebo veřejné správy

Druh možnosti využití

A - K využití výsledku jiným subjektem je vždy nutné nabytí licence